ALS For support and discussion of Amyotrophic lateral sclerosis (ALS), also referred to as "Lou Gehrig's Disease." In memory of BobbyB.


advertisement
Reply
 
Thread Tools Display Modes
Old 01-26-2007, 08:08 AM #1
BobbyB's Avatar
BobbyB BobbyB is offline
In Remembrance
 
Join Date: Aug 2006
Location: North Carolina
Posts: 4,609
15 yr Member
BobbyB BobbyB is offline
In Remembrance
BobbyB's Avatar
 
Join Date: Aug 2006
Location: North Carolina
Posts: 4,609
15 yr Member
Default Cannabinoid Agonist Significantly Increases ALS Life Span, Study Says

Cannabinoid Agonist Significantly Increases ALS Life Span, Study Says

Little Rock, AR: Administration of the selective cannabinoid agonist AM-1241 significantly increases the survival of mice with amyotrophic lateral sclerosis (ALS) and may ultimately lead to the development of new cannabis-based medications to treat the disease in humans, according to preclinical findings to be published in the Journal of Neurochemistry.

Investigators at the University of Arkansas, College of Medicine, reported that mice administered high daily doses of AM-1241 after ALS symptom onset lived up to 56 percent longer than controls.

"[T]he magnitude of effect produced by AM-1241 initiated at symptom onset rivals the best yet reported for any pharmaceutical agent, even those given pre-symptomatically," authors wrote. "[The] findings from this study indicate that [cannabinoid] agonists may ultimately be developed as novel therapeutic drugs that can be administered alone or in combination with other agents at symptom onset for the treatment of ALS in human patients."

Previous studies with THC report that it delays motor impairment and increases survival in animal models of ALS at rates slightly less than those obtained by the administration of low doses of AM-1241.

Amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, is a fatal neurodegenerative disorder that is characterized by the selective loss of motor neurons in the spinal cord, brain stem, and motor cortex. An estimated 30,000 Americans are living with ALS, which often arises spontaneously and afflicts otherwise healthy adults. More than half of ALS patients die within 2.5 years following the onset of symptoms.

Currently, no effective pharmaceutical medications exist to stave ALS progression.

Some investigators speculate that the endocannabinoid receptor system may protect against certain neurodegenerative disorders like ALS by exhibiting neuroprotective and anti-inflammatory actions to combat disease symptoms.

For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Full text of the study, "The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset," will appear in a forthcoming issue of the Journal of Neurochemistry. Additional information on cannabinoids and ALS is available in NORML's new report, "Emerging Clinical Applications for Cannabis and Cannabinoids," available online at: http://www.norml.org//index.cfm?Group_ID=7004.
__________________

.

ALS/MND Registry

.
BobbyB is offline   Reply With QuoteReply With Quote

advertisement
Old 01-26-2007, 08:13 AM #2
BobbyB's Avatar
BobbyB BobbyB is offline
In Remembrance
 
Join Date: Aug 2006
Location: North Carolina
Posts: 4,609
15 yr Member
BobbyB BobbyB is offline
In Remembrance
BobbyB's Avatar
 
Join Date: Aug 2006
Location: North Carolina
Posts: 4,609
15 yr Member
Default

Amyotrophic Lateral Sclerosis (ALS)





Join the Discussion


Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease, is a fatal neurodegenerative disorder that is characterized by the selective loss of motor neurons in the spinal cord, brain stem, and motor cortex. An estimated 30,000 Americans are living with ALS, which often arises spontaneously and afflicts otherwise healthy adults. More than half of ALS patients die within 2.5 years following the onset of symptoms.

A review of the scientific literature reveals an absence of clinical trials investigating the use of cannabinoids for ALS treatment. However, recent preclinical findings indicate that cannabinoids can delay ALS progression, lending support to anecdotal reports by patients that cannabinoids may be efficacious in moderating the disease’s development and in alleviating certain ALS-related symptoms such as pain, appetite loss, depression and drooling.[1]

Writing in the March 2004 issue of the journal Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders, investigators at the California Pacific Medical Center in San Francisco reported that the administration of THC both before and after the onset of ALS symptoms staved disease progression and prolonged survival in animals compared to untreated controls.[2]

Additional trials in animal models of ALS have shown that the administration of other naturally occurring and synthetic cannabinoids can also moderate ALS progression, but not necessarily impact survival.[3-4] One recent study demonstrated that blocking the CB1 cannabinoid receptor did extend life span in an ALS mouse model, suggesting that cannabinoids’ beneficial effects on ALS may be mediated by non-CB1 receptor mechanisms.[5]

Preclinical data has also shown that cannabinoids are neuroprotective against oxidative damage both in vitro[6] and in animals.[7] Cannabinoids’ neuroprotective action may be able to play a role in moderating ALS, which is characterized by excessive glutamate activity in the spinal cord.[8] At least one cannabinoid, delta-9-THC, has been shown to protect cultured mouse spinal neurons against excitotoxicity.[9]

As a result, some experts now recommend that “marijuana … be considered in the pharmacological management of ALS,”[10] and they believe that “further investigation into the usefulness of marijuana and … synthetic cannabinoid receptor agonists is warranted.”[11]
REFERENCES

[1] Amtmann et al. 2004. Survey of cannabis use in patients with amyotrophic lateral sclerosis. The American Journal of Hospice and Palliative Care 21: 95-104.

[2] Raman et al. 2004. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 5: 33-39.

[3] Weydt et al. 2005. Cannabinol delays symptom onset in SOD1 transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 6: 182-184.

[4] Bilsland et al. 2006. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. The FASEB Journal 20: 1003-1005.

[5] Ibid.

[6] Raman et al. 2004. op.cit.

[7] Hampson et al. 1998. Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences 95: 8268-8273.

[8] Carter and Weydt. 2002. Cannabis: Old medicine with new promise for neurological disorders. Current Opinion in Investigational Drugs 3: 437-440.

[9] Abood et al. 2001. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neuroscience Letters 309: 197-201.

[10] Carter and Rosen. 2001. Marijuana in the management of amyotrophic lateral sclerosis. The American Journal of Hospice and Palliative Care 18: 264-70.

[11] Carter et al. 2003. Drug therapy for amyotrophic lateral sclerosis: Where are we now? The Investigational Drugs Journal 6: 147-153.




Comments
From: billmay52@bellsouth.net (12/29/06 01:00:18)

I want to congratulate you - I administer several mj cigarettes, and I enjoy it plus it takes glacoma and makes it stay away. I am unified until the Law gets me
---------------------------------------
From: miksisjulie@yahoo.com (11/13/06 08:54:10)

my sister has ALS-Dr.'s put her on -pain medications,anti dpressants.She looks like a ZOMBIE. Last week i visited her and she looked awesome-healthy, no bags under her eyes, & moving around-she took herself off the pain killers and lit up a joint!!This is how she is handling her pain now -improvement- physical& emotional---MIRACULOUS!The change is great!I know she is still in pain but she's tuned in not tuned out on pain killers. Don't u think she should be in some kind of study or something???
---------------------------------------
From: Greg Carter, MD (09/13/06 02:08:57)

As always, Paul Armentano and NORML have put together an excellent, science based position paper, based on fact and logic, not paranoia and propaganda. Keep up the great work!
---------------------------------------
http://www.norml.org//index.cfm?Group_ID=7004
__________________

.

ALS/MND Registry

.
BobbyB is offline   Reply With QuoteReply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
Synthetic cannabinoid Nabilone significantly reduces spasticity-related pain wannabe Multiple Sclerosis 2 10-04-2006 07:28 PM
Stress Significantly and Quickly Hastens the Progress BobbyB ALS News & Research 0 08-30-2006 01:33 PM


All times are GMT -5. The time now is 02:49 AM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.